EverPoint Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

EverPoint Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-200,000	Closed	-$3.31M	–	555
2016 Q1	$3.31M	Buy	200,000 +100,000	+100%	+$1.75M	0.07%	278
2015 Q4	$2.17M	Hold	100,000	–	–	0.05%	373
2015 Q3	$1.98M	Buy	+100,000	New	+$3.16M	0.05%	332

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverPoint Asset Management's HZNP Position: Q4 2016 in Review

EverPoint Asset Management reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 22% in Q4 2016, selling an estimated $6.8M and leaving 1,300,000 shares worth $21M. The position accounts for 0.39% of the portfolio, ranked #62.

EverPoint Asset Management first reported a position in HZNP in Q3 2014 and has held it in 10 quarters since. The position peaked at $30.4M in Q3 2016. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

EverPoint Asset Management held 1,300,000 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $21M as of Q4 2016.
EverPoint Asset Management sold 375,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $6.8M.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.39% of EverPoint Asset Management's portfolio in Q4 2016, its #62 holding.
EverPoint Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014 and has held it in 10 quarters since.
EverPoint Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $30.4M in Q3 2016.
234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.